AR065918A1 - Composiciones farmaceuticas sinergicas que comprenden la combinacion de un inhibidor de la enzina 5 alfa-reductasa y un antagonista de los receptores 1-adrenergicos - Google Patents

Composiciones farmaceuticas sinergicas que comprenden la combinacion de un inhibidor de la enzina 5 alfa-reductasa y un antagonista de los receptores 1-adrenergicos

Info

Publication number
AR065918A1
AR065918A1 ARP080101373A ARP080101373A AR065918A1 AR 065918 A1 AR065918 A1 AR 065918A1 AR P080101373 A ARP080101373 A AR P080101373A AR P080101373 A ARP080101373 A AR P080101373A AR 065918 A1 AR065918 A1 AR 065918A1
Authority
AR
Argentina
Prior art keywords
antagonist
adrenergic
pharmaceutical
enzine
alfa
Prior art date
Application number
ARP080101373A
Other languages
English (en)
Inventor
Armenta Maria Elena Garcia
Murillo Josefina Santos
Ochoa Victor Guillermo Alvarez
Original Assignee
World Trade Imp Export Wtie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39808488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065918(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by World Trade Imp Export Wtie Ag filed Critical World Trade Imp Export Wtie Ag
Publication of AR065918A1 publication Critical patent/AR065918A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composiciones farmacéuticas que están compuestas por la combinacion sinérgica de un agente inhibidor de la enzima 5-reductasa, como lo son los principios activos: Finasterida o Dutasterida y un agente antagonista de los receptores -adrenérgicos,como lo son los principios activos: Alfuzosina o Doxazosina, mismos que se encuentran formulados en una sola unidad de dosificacion para ser administrada por vía oral en forma de tabletas, las cuales están indicadas para el tratamiento de laHiperplasia Protática Benigna, así como para el alivio de los síntomas manifestados por dicha enfermedad.
ARP080101373A 2007-04-02 2008-04-01 Composiciones farmaceuticas sinergicas que comprenden la combinacion de un inhibidor de la enzina 5 alfa-reductasa y un antagonista de los receptores 1-adrenergicos AR065918A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2007003949A MX2007003949A (es) 2007-04-02 2007-04-02 Composiciones farmaceuticas sinergicas que comprenden la combinacion de un inhibidor de la enzima (-reductasa y un antagonista de los receptores 1 (-adrenergicos.
PCT/MX2008/000012 WO2008120967A1 (es) 2007-04-02 2008-01-29 COMPOSICIONES FARMACÉUTICAS SINERGICAS QUE COMPRENDEN LA COMBINACIÓN DE UN INHIBIDOR DE LA ENZIMA 5 α-REDUCTASA Y UN ANTAGONISTA DE LOS RECEPTORES 1 α- ADRENERGICOS.

Publications (1)

Publication Number Publication Date
AR065918A1 true AR065918A1 (es) 2009-07-08

Family

ID=39808488

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101373A AR065918A1 (es) 2007-04-02 2008-04-01 Composiciones farmaceuticas sinergicas que comprenden la combinacion de un inhibidor de la enzina 5 alfa-reductasa y un antagonista de los receptores 1-adrenergicos

Country Status (10)

Country Link
EP (1) EP2156836B1 (es)
AR (1) AR065918A1 (es)
BR (1) BRPI0809309A2 (es)
CL (1) CL2008000964A1 (es)
CO (1) CO6140029A2 (es)
EC (2) ECSP099649A (es)
ES (1) ES2656426T3 (es)
GT (1) GT200900275A (es)
MX (1) MX2007003949A (es)
WO (1) WO2008120967A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1103204A2 (pt) * 2011-06-03 2014-02-25 Eurofarma Lab S A Composição farmacêutica para o tratamento de hiperplasia prostática benigna
US20200129583A1 (en) * 2017-06-30 2020-04-30 Antev Limited Composition for treating acute urinary retention

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ241979A (en) * 1991-03-20 1996-01-26 Merck & Co Inc Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
AU7703700A (en) * 1999-09-22 2001-04-24 Merck & Co., Inc. Treatment of lower urinary tract symptoms and pharmaceutical compositions for use therein

Also Published As

Publication number Publication date
CO6140029A2 (es) 2010-03-19
MX2007003949A (es) 2009-02-25
EP2156836B1 (en) 2017-10-18
BRPI0809309A2 (pt) 2014-10-14
EP2156836A1 (en) 2010-02-24
ECSP099649A (es) 2009-10-30
ES2656426T3 (es) 2018-02-27
GT200900275A (es) 2016-01-21
WO2008120967A1 (es) 2008-10-09
ECSP099650A (es) 2009-10-30
EP2156836A4 (en) 2011-01-26
CL2008000964A1 (es) 2009-03-20

Similar Documents

Publication Publication Date Title
CU20130069A7 (es) Derivados de 2,3-dihidroimidazo[1,2-c] quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermeddes asociadas a la angiogénesis
DK2321321T3 (da) Triazolo [4,5-d]pyramidinderivater og anvendelse deraf som purinreceptorantagonister
UY32820A (es) Composiciones dermatologicas de antagonistas del receptor dp2
AR054094A1 (es) Tratamientos de cancer
ES2526606T3 (es) Composición farmacéutica sólida que comprende amlodipina y losartán
EA201071291A2 (ru) Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств
AR051968A1 (es) Metodos y composiciones que utilizan inhibidores de jnk para el tratamiento y manejo de la lesion del sistema nervioso central
GT200600028A (es) Compuestos y composiciones como inhibidores de proteina kinasa
PA8746901A1 (es) Formulaciones de un compuesto en forma de polvo seco y usos de estas
TR201905423T4 (tr) 4-amino-2-(2,6-dioksopiperidin-3-il)izindolin-1,3-dion'un formülasyonları
CO6341574A2 (es) Composiciones de antagonistas dl pd-1 y metodos de uso
CR20110596A (es) Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas
CO6480932A2 (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida.
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
UY28517A1 (es) Nueva combinación
CL2007003251A1 (es) Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer.
CO6280488A2 (es) Combinacion farmaceutica
PE20130147A1 (es) Combinacion farmaceutica de teobromina y un agente antitusivo no opioide
AR065918A1 (es) Composiciones farmaceuticas sinergicas que comprenden la combinacion de un inhibidor de la enzina 5 alfa-reductasa y un antagonista de los receptores 1-adrenergicos
ECSP099734A (es) Composición farmaceutica que comprende la combinación de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante
AR083095A1 (es) Cocristal de aprepitant l-prolina y composicion farmaceutica
AR116592A1 (es) Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib
CO6640306A2 (es) Combinación de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso
AR066667A1 (es) Composiciones farmaceuticas que comrenden la combinacion de un agente derivado hidrogenado de lipstatina y un agente inhibidor de hmg coa reductasa
AR059081A1 (es) Composicion farmaceutica estable de carisoprodol y meloxicam

Legal Events

Date Code Title Description
FB Suspension of granting procedure